

July 7, 2026 (issued by Sales Planning Department)

株式会社日本バイオリサーチセンター

Nihon Bioresearch inc.

104, 6-chome, Majima, Fukuju-cho, Hashima, Gifu, 501-6251 Japan
Tel: +81-58-392-6222Web: <https://www.nbr.co.jp/en/>

▼Click here▼

We are AAALAC- and JAPIC-certified animal testing facility.

keyword



mini liver

liver

fibrosis

human liver

in vitro



Official website


Human 3D Mini Liver Disease Model

We will introduce a drug efficacy evaluation using a human 3D mini liver disease model (Cyfuse Biomedical K.K.).

Bezafibrate, a drug for hyperlipidemia, demonstrated efficacy in this model.



Test Method (example)

Medium was replaced from the day after obtaining cells 10 days after fibrosis induction (Day 0), and 10 μ M of bezafibrate is added at the time of the medium replacement.



Evaluation (example 1)

Evaluation item: Fibrous area of spheroid (picosirius red staining)




** : $p < 0.01$, vs control

Evaluation (example 2)

Evaluation items: AST, ALT, and TG in culture medium (automated biochemical analyzer)

Changes in AST, ALT, and TG in culture medium



Results

Compared with the control model, the area of fibrosis was significantly increased in the disease model. It was suggested that bezafibrate tended to suppress the progression of fibrosis.